Sugi Predict

Sugi Predict / Compounds / SCHEMBL3058890

SCHEMBL3058890

SCHEMBL3058890

O=C(Cl)c1ccc(CCl)o1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 4/20 0.45
▸ HTT P42858 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ POLB P06746 5/20 0.38
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ TSHR P16473 1/20 0.37
▸ KMT2A Q03164 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11832303 0.83 TDP1 (0.42) TDP1HTTSMN1; SMN2HPGDPOLB
SCHEMBL1669583 0.83 TDP1 (0.67) TDP1HTTSMN1; SMN2POLBHSD17B10
SCHEMBL19801525 0.81 TDP1 (0.44) TDP1HTTSMN1; SMN2HPGDPOLB
SCHEMBL4257916 0.81 NPC1 (0.46) TDP1HTTSMN1; SMN2HPGDPOLB
SCHEMBL855813 0.81 HTT (0.44) TDP1HTTSMN1; SMN2HPGDPOLB
SCHEMBL18640579 0.79 CA1 (0.52) TDP1HTTSMN1; SMN2HPGDPOLB
SCHEMBL1355720 0.78 MAPT (0.39) TDP1HTTHPGDCA1CA2
SCHEMBL3060942 0.78 SMN1; SMN2 (0.42) TDP1HTTSMN1; SMN2HPGDPOLB
SCHEMBL22680998 0.78 HTT (0.50) TDP1HTTSMN1; SMN2HPGDHSD17B10
SCHEMBL4672676 0.76 PTGER1 (0.45) TDP1HTTSMN1; SMN2HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115997003-B Irritation-reducing surfactants 联合利华知识产权控股有限公司 2024-12-27 — — CN disclosed
US-20230287299-A1 IRRITATION MITIGATING SURFACTANTS CONOPCO, INC., D/B/A UNILEVER (US) 2023-09-14 — — US disclosed
US-20230203379-A1 PROCEDURE FOR OBTAINING FLEXIBLE EXPANDABLE MATERIAL (FEM) RESISTANT TO COMBUSTION USING BIOPLASTIFICIZERS SUBOTIC, NEMANJA, MR. (RS) 2023-06-29 — — US disclosed
US-20230203379-A1 PROCEDURE FOR OBTAINING FLEXIBLE EXPANDABLE MATERIAL (FEM) RESISTANT TO COMBUSTION USING BIOPLASTIFICIZERS SUBOTIC, NEMANJA, MR. (RS) 2023-06-29 — — US disclosed
US-20230203379-A1 PROCEDURE FOR OBTAINING FLEXIBLE EXPANDABLE MATERIAL (FEM) RESISTANT TO COMBUSTION USING BIOPLASTIFICIZERS SUBOTIC, NEMANJA, MR. (RS) 2023-06-29 — — US disclosed
CN-112625014-B Method for preparing 2, 5-furan diformyl chloride from 5-chloromethyl furfural 国网安徽省电力有限公司电力科学研究院 2023-05-23 — — CN disclosed
EP-4176028-A1 IRRITATION MITIGATING SURFACTANTS Unilever IP Holdings B.V. (NL) 2023-05-10 — — EP disclosed
CN-115997003-A Irritation-reducing surfactants 联合利华知识产权控股有限公司 2023-04-21 — — CN disclosed
US-20220213410-A1 COMPOUND AND DETERGENT COMPOSITION Conopcuso, Inc., d/b/a UNILEVER (US) 2022-07-07 — — US disclosed
EP-3966301-A1 COMPOUND AND DETERGENT COMPOSITION UNILEVER GLOBAL IP LIMITED (GB) 2022-03-16 — — EP disclosed
US-6956040-B2 Oxazolidinone piperazinyl derivatives as potential antimicrobials RANBAXY LABORATORIES LIMITED (IN) 2005-10-18 — — US disclosed
US-20040254162-A1 Oxazolidinone derivatives as antimicrobials RANBAXY LABORATORIES LIMITED (IN) 2004-12-16 — — US disclosed
US-6734307-B2 USE AGAINST MULTIPLY RESISTANT GRAM POSITIVE PATHOGENS; HAVE A DIAZINE MOIETY ATTACHED TO THE PHENYLOXAZOLIDINONE WHICH IS FURTHER SUBSTITUTED BY HETEROCYCLIC, ARYL, SUBSTITUTED ARYL, HETEROAROAMATIC RING RANBAXY LABORATORIES LIMITED (IN) 2004-05-11 — — US disclosed
EP-1409465-A2 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES, LTD. (IN) 2004-04-21 — — EP disclosed
CN-1447808-A Oxazolidinone derivatives as anticrobials RANBAXY LAB LTD (IN) 2003-10-08 — — CN disclosed
US-20030119817-A1 Oxazolidinone derivatives as potential antimicrobials MEHTA ANITA (IN) 2003-06-26 — — US disclosed
EP-1303511-A1 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES, LTD. (IN) 2003-04-23 — — EP disclosed
WO-2003007870-A2 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES LIMITED (IN) 2003-01-30 — — WO disclosed
US-20020103186-A1 Oxazolidinone derivatives as antimicrobials disease RANBAXY LABORATORIES LIMITED (IN) 2002-08-01 — — US disclosed
WO-2002006278-A1 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES LIMITED (IN) 2002-01-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119817-A1 Oxazolidinone derivatives as potential antimicrobials OXA1L, PDK4, SDHA TDP1 3452/4885HTT 2304/4885SMN1; SMN2 3652/4885
US-20020103186-A1 Oxazolidinone derivatives as antimicrobials disease OXA1L, MLYCD, TBCD TDP1 3679/4885HTT 1512/4885SMN1; SMN2 2876/4885
US-20220213410-A1 COMPOUND AND DETERGENT COMPOSITION WASHC5, DEGS1, WASHC4 TDP1 1780/4885HTT 1054/4885SMN1; SMN2 569/4885
US-20040254162-A1 Oxazolidinone derivatives as antimicrobials PPARD, PDK4, OXA1L TDP1 3772/4885HTT 2759/4885SMN1; SMN2 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.